Zymeworks Presents New Data from Multiple Development Programs at 2025 AACR Annual Meeting
Zymeworks Inc. (ZYME)
Last zymeworks inc. earnings: 3/2 04:15 pm
Check Earnings Report
US:NYSE Investor Relations:
ir.zymeworks.com/overview
Company Research
Source: GlobeNewswire
Six posters highlight continued progress across antibody-drug conjugate and T cell engager platforms Novel T cell engager ZW209 demonstrates durable activity in small cell lung cancer; IND submission expected in 1H-2026 VANCOUVER, British Columbia, April 25, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced the presentation of six posters with new preclinical data from its preclinical, development-stage, and clinical programs at the American Association for Cancer Research (AACR) Annual Meeting being held April 25-30, 2025 in Chicago, IL. “The breadth of data shared at AACR highlights the strength of our oncology portfolio across antibody-drug conjugates and T cell engagers, and demonstrates the novel approaches we employ using ea
Show less
Read more
Impact Snapshot
Event Time:
ZYME
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ZYME alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ZYME alerts
High impacting Zymeworks Inc. news events
Weekly update
A roundup of the hottest topics
ZYME
News
- Zymeworks (NASDAQ:ZYME) was upgraded by analysts at Wells Fargo & Company from a "hold" rating to a "strong-buy" rating.MarketBeat
- Zymeworks (NYSE:ZYME) was upgraded by analysts at Wells Fargo & Company from a "cautious" rating to an "overweight" rating.MarketBeat
- Zymeworks (NASDAQ:ZYME) was upgraded by analysts at Citizens Jmp to a "strong-buy" rating.MarketBeat
- Zymeworks (NYSE:ZYME) is now covered by analysts at Citizens Jmp. They set an "outperform" rating and a $32.00 price target on the stock.MarketBeat
- Zymeworks (NYSE:ZYME) was given a new $32.00 price target on by analysts at JMP Securities.MarketBeat
ZYME
Earnings
- 11/6/25 - Beat
ZYME
Sec Filings
- 11/24/25 - Form 144
- 11/21/25 - Form 144
- 11/19/25 - Form SCHEDULE
- ZYME's page on the SEC website